Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. reported significant growth in net product revenues and gross profit for Q1 2025, driven primarily by domestic sales of its lead product ARAKODA® [5][6]. Financial Highlights - Net product revenues for Q1 2025 increased by approximately 55% year-over-year, reaching about $163.6 thousand, up from $105.7 thousand in Q1 2024 [6]. - Gross profit for Q1 2025 was approximately $90.3 thousand, representing a 124% increase from approximately $40.2 thousand in Q1 2024 [5][6]. - Operating expenses rose to approximately $2.09 million in Q1 2025, compared to approximately $1.41 million in Q1 2024, with increased expenditures in sales and investor-related services contributing to this rise [6]. - The net loss attributable to common shareholders for Q1 2025 was approximately $2.01 million, or ($1.56) per share, contrasting with a net income of approximately $308.7 thousand, or $1.83 per share in Q1 2024 [6].
60 Degrees Pharmaceuticals Announces First Quarter 2025 Results